Occlusive Disease: Aorta & Iliac Arteries
Low-dose rivaroxaban (2.5 mg orally twice daily) with aspirin 100 mg orally daily reduces both major cardiovascular and limb-related adverse events in symptomatic patients.
Occlusive Disease: Femoral & Popliteal Arteries
After a meta-analysis of clinical trial data showed increased mortality at 3–5 years after treatment with paclitaxel-coated devices, the FDA performed an independent review and recommends judicious use of the devices. Ongoing trials, such as SWEDEPAD, are expected to provide additional data on the risks and benefits of paclitaxel devices.